August 28, 2017
The Ministry of Health, Labor and Welfare (MHLW) on August 25 approved additional indications for a batch of drugs including Novartis Pharma’s Revolade (eltrombopag) and Chugai Pharmaceutical’s Actemra (tocilizumab). Revolade, a treatment for chronic idiopathic thrombocytopenic purpura, is now approved...read more